Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment.
Marco Carlo MerlanoMatteo PaccagnellaNerina DenaroAndrea AbbonaDanilo GaliziaDario SangioloLoretta GammaitoniErika FiorinoSilvia MineiPaolo BossiLisa LicitraOrnella GarronePublished in: Cancers (2023)
In this small population with poor clinical characteristics, this study highlights the prognostic role of IL-6 and TGF-β. Nivolumab treatment is associated with a positive modulation of some Th1 cytokines, but it does not correlate with the outcome.